Head-To-Head Survey: Disaboom (OTCMKTS:MEDH) versus PAVmed (NASDAQ:PAVM)

Disaboom (OTCMKTS:MEDH) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Disaboom and PAVmed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disaboom	0	0	0	0	0.00
PAVmed	1	1	1	0	2.00

PAVmed has a consensus price target of $65.00, indicating a potential upside of 807.82%. Given PAVmed’s stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Disaboom.

Earnings & Valuation

This table compares Disaboom and PAVmed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disaboom	$1.76 million	0.55	$270,000.00	$0.01	0.14
PAVmed	$70,000.00	102.29	$400,000.00	($22.77)	-0.31

PAVmed has lower revenue, but higher earnings than Disaboom. PAVmed is trading at a lower price-to-earnings ratio than Disaboom, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Disaboom has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Insider and Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. 5.8% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Disaboom and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Disaboom	15.34%	N/A	N/A
PAVmed	564.79%	-242.99%	-17.25%

Summary

PAVmed beats Disaboom on 8 of the 14 factors compared between the two stocks.

About Disaboom

Dazed, Inc. focuses on retail, distribution, hospitality, licensing, and franchising of portfolio of counterculture brands. The company was formerly known as MedX Holdings, Inc. and changed its name to Dazed, Inc. in October 2022. Dazed, Inc. was founded in 2004 and is based in Cheyenne, Wyoming.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.